Embryonic Stem Cell News and Research

RSS

Stanford researchers use DNA minicircles to induce pluripotency in stem cells from human fat

Tiny circles of DNA are the key to a new and easier way to transform stem cells from human fat into induced pluripotent stem cells for use in regenerative medicine, say scientists at the Stanford University School of Medicine. Unlike other commonly used techniques, the method, which is based on standard molecular biology practices, does not use viruses to introduce genes into the cells or permanently alter a cell's genome.

8 Feb 2010

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

In the 7 Feb. 2010 issue of the journal Nature, scientists at the Genome Institute of Singapore (GIS), report that a genetic molecule, called Tbx3, which is crucial for many aspects of early developmental processes in mammals, significantly improves the quality of stem cells that have been reprogrammed from differentiated cells.

7 Feb 2010

Renova Life moves into Mtech TAP incubator

Renova Life Inc., a company developing research and testing models for human cardiovascular disease, has joined the Maryland Technology Enterprise Institute (Mtech) Technology Advancement Program (TAP) incubator, institute officials announce today.

6 Feb 2010

DOD to investigate mental health care at Camp Lejeune, also will stock morning-after pill

The Associated Press reports that, according to Rep. Walter Jones, R-N.C., "The Defense Department will investigate complaints of substandard mental health care for Marines at Camp Lejeune. ... Public questions about the quality of mental health care provided by a private contractor at the base were raised last year by the September firing of Dr. Kernan Manion, a brain trauma specialist who had complained to commanders about poor facilities, inadequate care programs and weak security.

5 Feb 2010

International Stem Cell opens new cell production facility in Oceanside, California

International Stem Cell Corporation, www.internationalstemcell.com, announced today that its new cell production facility has passed final building inspection, which will enable development and manufacturing of the company and its partners’ clinical-grade stem cell products.

5 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

Mapping of human genome modification during embryonic development

Scientists at The Genome Institute of Singapore (GIS) and The Scripps Research Institute (TSRI) led an international effort to build a map that shows in detail how the human genome is modified during embryonic development.

4 Feb 2010

Study sheds new light on cancer metastasis

Some cells are natural rule-breakers. Neural crest cells for example, not only migrate throughout the body during development (most cells are more selective in their wandering), they are also more developmentally flexible than their predecessors (a no-no for nearly all cell types).

4 Feb 2010

Transplantation of pulmonary progenitor cells derived from hESCs promising for acute lung injury

Stem cell researchers exploring a new approach for the care of respiratory diseases report that an experimental treatment involving transplantable lung cells was associated with improved outcomes in tests on mice with acute lung injury. The lung cells were derived from human embryonic stem cells (hESCs). Findings by investigators at The University of Texas Health Science Center at Houston are scheduled to appear in the March issue of Molecular Therapy.

4 Feb 2010

New 3D scaffold for stem cell renewal

Medical researchers were shocked to discover that virtually all human embryonic stem cell lines being used in 2005 were contaminated. Animal byproducts used to line Petri dishes had left traces on the human cells. If those cells had been implanted in a human body they likely would have been rejected by the patient's immune system.

3 Feb 2010

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejection

29 Jan 2010

New technique could reduce animal use in gene study

A new method of priming early embryos to form embryonic stem (ES) cells has allowed ES cells to be derived from mice used in diabetes research for the first time.

28 Jan 2010

CSCs elimination could hold the key to fight ovarian cancer

Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ovarian cancer, which has been notoriously difficult to detect and treat, according to new findings published this week in the journal Oncogene by Yale School of Medicine researchers.

28 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Findings may point toward potential therapies for type 2 diabetes

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells.

27 Jan 2010

hESC "reporter" line to measure endothelial cell production and activity

New York Stem Cell Foundation (NYSCF)-Druckenmiller Fellow, Daylon James, PhD, of Weill Cornell Medial College, is lead author on a study defining conditions for generating a plentiful supply of endothelial (vessel lining) cells that are suitable for therapeutic use. Dr. James and his colleagues created a human embryonic stem cell (hESC) "reporter" line that can be used to measure endothelial cell production and activity.

22 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

ACT receives FDA notification regarding its embryonic stem cell trials for SMD

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).

9 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Biologists have developed an efficient way to genetically modify human embryonic stem cells. Their approach, which uses bacterial artificial chromosomes to swap in defective copies of genes, will make possible the rapid development of stem cell lines that can both serve as models for human genetic diseases and as testbeds on which to screen potential treatments, they say.

8 Jan 2010

Embryonic Stem Cell News and Research

Stanford researchers use DNA minicircles to induce pluripotency in stem cells from human fat

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

Renova Life moves into Mtech TAP incubator

DOD to investigate mental health care at Camp Lejeune, also will stock morning-after pill

International Stem Cell opens new cell production facility in Oceanside, California

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Mapping of human genome modification during embryonic development

Study sheds new light on cancer metastasis

Transplantation of pulmonary progenitor cells derived from hESCs promising for acute lung injury

New 3D scaffold for stem cell renewal

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New technique could reduce animal use in gene study

CSCs elimination could hold the key to fight ovarian cancer

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Findings may point toward potential therapies for type 2 diabetes

hESC "reporter" line to measure endothelial cell production and activity

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

ACT receives FDA notification regarding its embryonic stem cell trials for SMD

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News